Summary

  • The FDA’s approval of Fayuvi shifts the central Sanfilippo treatment question from development to access, but Sydney Lupkin’s NPR account leaves eligibility, patient liability, referral, financing, capacity and timing unresolved.
  • Ultragenyx’s 2022 acquisition transferred commercial control over Fayuvi to the rights holder while earlier families and foundations financed experimental risk, without giving those funders a documented governance role in pricing or delivery.
  • Ultragenyx CEO Emil Kakkis’s no-price commitment and the treatment’s nearly $4 million price make broad access possible but do not demonstrate either exclusion or unrestricted access because the access mechanics are absent.
  • Haiyan Fu, the O’Neill family and eight patient foundations completed the development chain, while the next phase requires institutions to resolve early identification, clinical selection, administration, follow-up and disputes.

The Food and Drug Administration approved Fayuvi in September as a one-time infusion for Sanfilippo syndrome, following laboratory work begun in the late 1990s, patient-supported financing, a first human trial launched in May 2016 and Ultragenyx’s development of the therapy after acquiring its rights in 2022. That documented sequence supports an analytical inference rather than an FDA determination: approval moves the unresolved question from whether the treatment can be developed to how eligible children can receive it, when, where, under what patient-liability terms and with what supporting evidence. Ultragenyx set the price at nearly $4 million, tying it for the second-most-expensive gene therapy ever according to 46brooklyn, while Kakkis said the company would treat every patient regardless of price. The account supports the possibility of broad access, not a demonstrated access system: the absence of procedural details neither establishes that patients are being denied treatment nor establishes that treatment is universally available without household charges or geographic barriers.

Approval ends one institutional chain and opens another

The FDA’s approval followed, rather than displaced, a distributed development effort. Fu’s mouse research at Nationwide Children’s Hospital connected the disorder’s biology to a modified virus that could deliver a working copy of the faulty gene to patients’ cells. The article describes Sanfilippo syndrome as an inherited disorder in which children cannot break down heparin sulfate, a molecule critical to normal cell function; accumulation of that substance contributes to severe complications, including loss of speech and walking and seizures.

Fu said she thought in 2009 that she might have to stop, but families of children with Sanfilippo supplied funding and encouraged her to continue. Eight patient foundations sustained the laboratory work until it was ready for the first human trial. Their role was a funding bridge between affected families and the academic laboratory rather than reliance on one large donor.

The O’Neill household was simultaneously a patient family, fundraiser and communications bridge. Eliza O’Neill’s family began the Cure Sanfilippo Foundation, which it continues to run, and its 2014 Saving Eliza video campaign raised $2 million. That money helped finance the first human trial, which began in May 2016, while the campaign also connected affected families with public visibility and trial participation.

Ultragenyx acquired the therapy’s rights in 2022, continued studying it and submitted data to the FDA. The agency approved the treatment in September, after which the one-time infusion received the name Fayuvi. Approval thus concludes a chain that combined scientific continuity, philanthropic support, family advocacy, regulatory review and commercial development. It begins a different coordination problem: clinical selection, patient-liability terms, referral, financing, manufacturing and treatment-site capacity, administration, follow-up and dispute resolution now require new institutional handoffs.

Commercial control and distributed responsibility

The development history contains two consequential resource-transfer points. Philanthropic support financed the experimental phase before a commercial company entered the sequence. Ultragenyx’s later acquisition connected that research lineage to the rights holder that now controls commercial development, price and delivery. The source documents no formal governance role for the families, foundations or researcher in the subsequent pricing and delivery decisions.

Responsibility for the research was also distributed. Fu and Nationwide Children’s Hospital supplied scientific continuity. Patient foundations and affected families supplied financial support and organizational reach. The O’Neill campaign supplied both capital and public visibility. The FDA supplied regulatory approval. Ultragenyx now holds the formal commercial authority, and clinicians and treatment sites will need to carry out patient selection and administration.

That allocation creates a mismatch between influence and exposure. Earlier funders and families carried the financial and personal risk of a program that remained experimental for years, while the present rights holder controls commercial terms. The article does not establish that the historical delay reflected present misconduct or bad faith, and it does not establish that a manufacturer’s list price determines what any family will owe. It does establish that a network once capable of sustaining research must now determine how access is financed and delivered.

Stakeholders, interests and constraints

Children with Sanfilippo and their caregivers. The article documents progressive loss of abilities and severe complications. Kakkis said earlier treatment produces better results because more brain function remains, and Ultragenyx stated that it would treat every patient regardless of price. Timely clinical benefit, treatment suited to the child’s condition, developmental and functional well-being, reduced family burden, avoidance of household liability and practical access to treatment sites are analytical inferences rather than motives expressly stated by affected families. High urgency and legitimacy appear plausible, while individual formal power appears low. Collective advocacy may increase practical influence, but the source establishes no governance seat or bargaining record.

Ultragenyx’s announced commitment is the clearest treatment route visible in the account, but the absence of eligibility and billing terms prevents it from functioning as a complete alternative to a negotiated agreement. Fundraising is the only fallback mechanism documented in the article, and its present availability and scalability are unknown. Patient charges, nonmedical delay or geographic exclusion would conflict with the families’ documented need for timely treatment without household liability or impractical travel, although the source does not establish whether any family currently has a live alternative. Age, disease stage and family circumstances differ, but the article establishes no differences in household resources, geography or care priorities.

The O’Neill family, patient foundations and affected families. The O’Neills raised $2 million and continue to run the Cure Sanfilippo Foundation; eight foundations sustained Fu’s research; and some families that supported the research lost children before approval. Their interests include research continuity, representative participation, stewardship of contributed funds, continued advocacy and treatment-access planning, inferred from documented conduct rather than expressly stated motives. Their legitimacy and urgency appear substantial. Their collective influence may also be substantial, but the source provides no governance or negotiating record.

Continued fundraising, advocacy and research support are documented activities, but they have not demonstrated systemwide access. Their scale remains unestablished: they financed an initial trial rather than created an access system for every child. The article also does not compare the foundations’ priorities or resources.

Haiyan Fu and Nationwide Children’s Hospital. Fu conducted mouse gene-therapy work from the late 1990s, said families’ funding allowed it to continue and later described approval as good news accompanied by mixed emotions: “It shouldn’t take this long.” Research continuity and translation from laboratory work into a human trial appear to be the relevant institutional interests; the source does not establish a personal or institutional-recognition motive. Subject-matter legitimacy and a bridging role appear substantial, but the source does not independently establish formal power or urgency.

The historical delay created a temporal mismatch with families whose treatment opportunities may narrow as children age. The article reports no current dispute or communication breakdown between Fu, the foundations and the commercial rights holder.

Ultragenyx. The company acquired the rights in 2022, continued studying the therapy, submitted data to the FDA, set a price of nearly $4 million, said it would treat every patient regardless of price and treated a few children. Broad patient reach, delivery safety and effectiveness, operational capacity and financial sustainability appear to be relevant interests inferred from the company’s commercial role, although the article does not state them as corporate motives.

Ultragenyx appears to hold substantial formal power because it controls the rights and sets the price. The source establishes no development-cost-recovery objective, financing arrangement, cost estimate, eligibility framework, treatment duration, manufacturing capacity, billing mechanics or third-party reimbursement plan. Continued treatment without patient payment is the company’s stated position, but its financing remains unestablished and cannot be treated as an implemented fallback. The absence of cost, reimbursement, capacity and other financial data prevents calculation of a defensible financial walk-away point. Failure to operationalize the access commitment could affect financial viability and public confidence, although the source reports no access outcome demonstrating either effect.

Food and Drug Administration. The agency approved Fayuvi in September after Ultragenyx submitted data. Safety, effectiveness and an accurate indication appear to be relevant approval functions, but the source does not describe the agency’s internal priorities. The FDA’s formal regulatory authority is evident. The article assigns price-setting to Ultragenyx and does not describe an FDA role in Fayuvi’s price. It reports no postmarket negotiation or enforcement issue, so an alternative-to-negotiated-agreement analysis for the agency is not supported by the record.

Clinicians and treatment sites. No clinician or treatment site speaks for Fayuvi treatment in the article. Appropriate patient selection, safety, capacity, consistent referral and continuity of care appear to be interests associated with the clinical-delivery function. Those parties could have high legitimacy and urgency, but their formal power, positions and capacity cannot be assessed because the source does not describe a referral or delivery system. Their operational interest lies in receiving appropriate referrals and administering the infusion.

Insurers, public programs and other payers. No payer or policymaker is identified. Coverage rules, clinical value, public spending and consistency of decisions are analytical categories rather than reported positions. This group may hold substantial formal decision-making power, but the source establishes neither its membership nor its stance. It would be unsupported to state that payers will accept or reject Fayuvi; their criteria, alternatives, urgency and reservation points cannot be determined.

Schools and developmental-service providers. The article reports that Eliza attends school but identifies no school or service provider as a participant in Fayuvi access. Inclusion, appropriate services and coordination with treatment and family care appear to be relevant interests given her developmental needs. Their formal power appears lower, but the source provides no basis for measuring their influence or continuing relevance.

Access mechanisms and decision standards

What is established is that a family may seek treatment under Ultragenyx’s announced commitment, while the article does not establish how patient charges, eligibility, referrals, geography or capacity are handled. That is a visible route, not a complete alternative to a negotiated agreement. No formal access negotiation, referral agreement, financing agreement, assistance program or dispute-resolution procedure is reported. The mechanisms below are therefore prospective designs rather than descriptions of existing arrangements.

A written, company-backed access covenant could specify zero patient liability, treatment-entry procedures and resolution of site and geographic barriers. Such a covenant would operationalize Kakkis’s announced commitment, but no written covenant is described in the account.

A reimbursement or sponsor arrangement could move the nearly $4 million price away from family ledgers while giving Ultragenyx a predictable payment source. The article identifies no sponsor or payer terms, leaving this mechanism available but unreported.

If treatment capacity or funds were limited, an independent capacity protocol could sequence treatment by diagnosis age and baseline neurological function while preventing ability to pay from determining first access. Such a protocol would require evidence beyond Kakkis’s statement, and the source does not disclose treatment capacity.

A long-term outcomes registry paired with referral and navigation could connect early identification, administration and follow-up. Referral and navigation could run through the foundations and clinical network, whose fundraising and organizing capacity is documented, although the foundations’ agreement to perform those additional roles is unknown.

An alternate-site referral or later-funding route could preserve additional choices. The article identifies no procedure, referral rule or funding cycle, and the availability of either route would require verification.

A case-specific review procedure could address an eligibility or payment disagreement, but the source names no panel, standard or appeal route. The procedure’s credibility would depend on affected parties participating in selecting the reviewer or establishing the standard.

Collective engagement through patient foundations and public advocacy could seek consistent access criteria. The O’Neill campaign demonstrates organizational capacity, but it does not establish that the same approach would produce commercial access agreements.

Among possible objective standards, independent review of durable outcomes stratified by diagnosis age and baseline function is the strongest supported shared clinical criterion because it corresponds to the reported timing rationale and offers a more defensible basis for allocation than a price formula alone. It remains an analytical proposal rather than an adopted standard. Other prospective standards include published clinical eligibility criteria with an equal-treatment rule, independent review of disputed cases and comparable cost-and-outcome evidence. The source supplies no adopted protocol, reviewer or comparator, and parties could disagree about which therapies qualify as comparable.

FDA approval supplies an external regulatory reference point, but the article does not reproduce the supporting evidence or show that approval resolves comparative effectiveness, affordability, eligibility or budget impact.

The record also establishes several limits. Patient charges, nonmedical delay and geographic exclusion conflict with the family interest in timely treatment without household liability or impractical travel. Continued fundraising and advocacy can support research and organization but have not demonstrated systemwide access, and their present scale is unknown. Ultragenyx’s commitment cannot be converted into a defensible financial walk-away point because the source provides no cost, reimbursement or capacity data. Payer acceptance, rejection, coverage conditions and reservation points remain unknown because no payer position is documented.

Clinical timing and the next institutional handoffs

Clinical timing is part of the access problem rather than a separate administrative detail. Kakkis said treatment works best in younger children because more brain function remains, and he said Ultragenyx had treated a few children at six months old who had done well. Under that stated rationale, waiting, delayed diagnosis and elapsed time can narrow the opportunity for benefit. The article supplies no comparative outcomes, adverse-event data or peer-reviewed evidence substantiating the comparative age effect.

Eliza O’Neill was the first patient treated in the 2016 clinical trial, at age six. Her ability to speak did not return, although she communicates with picture cards and devices, attends school and learned to float in a pool. She was almost 17 at the time of the NPR account. Her experience connects the infusion to continuing developmental services and family care, but it does not establish the treatment’s average effect. The source provides no comparison group or complete distribution of trial outcomes, leaving room for families, researchers and prospective payers to develop different expectations about urgency and value.

Fu’s assessment that approval carried mixed emotions reflects a development process that took more than a decade. Some affected families lost children before approval, while children diagnosed later may already have lost ground. That history establishes a temporal and emotional mismatch; it does not establish bad faith, an active dispute or present intent.

Institutional control remains asymmetrical. Ultragenyx holds formal authority over price and commercial delivery, while affected families possess urgency and collective experience but no documented governance role over those terms. A manufacturer’s list price alone cannot establish what any family will owe.

Children who died before approval, children not yet diagnosed and children without a referral or treatment route are not represented by quoted organizations in the approval announcement. Their absence from the public announcement does not reduce the consequences of eligibility, financing and capacity decisions.

Moving Fayuvi from approval toward treatment now requires a documented pathway for early identification, eligibility, referral, patient-liability terms, financing, site capacity, administration, follow-up and dispute resolution. The unresolved operational questions are who is treated, who pays, how quickly treatment begins, where it occurs and what evidence supports allocation.

Framing and evidence boundaries

Lupkin’s account brings together three analytically distinct layers: a long, patient-supported research history; regulatory approval; and a high price paired with a commitment to treat patients regardless of price. The development history, the regulatory event and the unresolved access system should not be treated as interchangeable evidence.

The article reports no finding of discriminatory denial, misconduct or bad faith. Historical delay cannot by itself determine present intent, and Ultragenyx’s price cannot by itself determine a family’s liability. Kakkis’s statement also does not define whether treating patients regardless of price means zero patient liability, a broader access pledge or some combination. Written access, billing and reimbursement terms would be needed before the commitment could be treated as a uniform process.

Eliza O’Neill’s experience cannot establish average efficacy, and the executive’s age-related statement is not a substitute for comparative trial evidence.

The NPR account remains the source for the September approval, the nearly $4 million price and 46brooklyn ranking, the $2 million campaign total and May 2016 trial start, the 2022 rights acquisition and the age-related treatment statement. The available material provides no independent external corroboration for those points, so they remain externally unverified rather than discredited. Relevant records for independent verification would include the FDA approval document and label, Ultragenyx and 46brooklyn price documentation, trial and acquisition records, peer-reviewed clinical evidence, published access and billing terms, payer coverage decisions and treatment-capacity records.

Analytical techniques used in this piece

This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.

Principled Negotiation
Works a negotiation from interests, options, and objective criteria rather than positions.
Relationship Mapping
Extracts the network of ties among people, institutions, and entities.
Stakeholder Mapping
Charts the parties to a situation — their interests, power, and alignments.